The Phosphodiesterase 3 pipeline drugs market research report outlays comprehensive information on the Phosphodiesterase 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Phosphodiesterase 3 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Respiratory, Infectious Disease, and Oncology which include the indications Cardiovascular, Acute Coronary Syndrome, Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Gastrointestinal Stromal Tumor (GIST), and Metastatic Uveal Melanoma. It also reviews key players involved in Phosphodiesterase 3 targeted therapeutics development with respective active and dormant or discontinued products.
The Phosphodiesterase 3 pipeline targets constitutes close to 16 molecules. Out of which, approximately 14 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, and Preclinical stages are 1, 3, 5, 2, and 3 respectively. Similarly, the universities portfolio in Discovery comprises 2 molecule.
Phosphodiesterase 3 overview
Phosphodiesterase 3 (PDE3) is a phosphodiesterase that belongs to at least 11 related gene families that are different in their primary structure, substrate affinity, responses to effectors, and regulation mechanism. It is involved in regulation of cardiac and vascular smooth muscle contractility. It consists of two members, PDE3A and PDE3B.
For a complete picture of Phosphodiesterase 3’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
